Advertisement

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Varsha Gandhi, PhD, on Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement

Oct

21

Today In Oncology

Claudia Henschke, PhD, MD Finding Lung Cancer in Time

Starting Surveillance Colonoscopy After High-Risk Adenoma Removal When Is the Right Time

Evolving Strategies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

AI Model Based on Facial Image Analysis Estimates Biological Age and Mortality Risk in Patients With Cancer

Community Oncology Practices Bring Advances in Cancer Testing and Treatment Closer to Patients

Advertisement

© 2026 HSP News Service, L.L.C.